Tetradecanoylphorbol acetate - Biosuccess Biotech/Rich Pharmaceuticals

Drug Profile

Tetradecanoylphorbol acetate - Biosuccess Biotech/Rich Pharmaceuticals

Alternative Names: PD-616; Phorbol 12-myristate 13-acetate; Phorbol myristate acetate; PMA; RP 323; TPA

Latest Information Update: 22 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rutgers; Zhengzhou University
  • Developer Biosuccess Biotech; Rich Pharmaceuticals; Rutgers
  • Class Antineoplastics; Antiretrovirals; Phorbol esters; Small molecules
  • Mechanism of Action Apoptosis stimulants; Mitogen-activated protein kinase modulators; Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia
  • Phase I/II Hodgkin's disease; Myelodysplastic syndromes
  • No development reported HIV infections; Stroke

Most Recent Events

  • 15 Mar 2018 Clinical trials in Acute myeloid leukaemia in China (IV) before March 2018
  • 14 Mar 2018 Phase-I/II clinical trials in Hodgkin's disease in USA (IV)
  • 01 Mar 2018 Phase-I clinical trials in Hodgkin's disease in USA (IV) before March 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top